<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Superior pulmonary sulcus (Pancoast) tumors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Superior pulmonary sulcus (Pancoast) tumors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Superior pulmonary sulcus (Pancoast) tumors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Selim M Arcasoy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven E Schild, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ticiana Leal, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rogerio C Lilenbaum, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Vallières, MD, FRCSC</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Superior sulcus tumors were first described in 1838, but they were an obscure entity until the reports of Henry Pancoast in the first third of the 20th century [<a href="#rid1">1</a>]. Pancoast mistakenly believed that these neoplasms arose from embryonal rests of the fifth branchial cleft; other investigators subsequently recognized the pulmonary origin of the vast majority of these malignancies.</p><p>Since Pancoast original reports, the terms "Pancoast tumors," "Pancoast-Tobias tumors," "superior sulcus tumors," or "superior pulmonary sulcus tumors" have been applied to neoplasms located at the apical pleuropulmonary groove, adjacent to the subclavian vessels  (<a class="graphic graphic_figure graphicRef89038" href="/d/graphic/89038.html" rel="external">figure 1</a>) [<a href="#rid2">2-4</a>]. The actual pulmonary sulcus comprises the thoracic costovertebral gutter on either side of the vertebral column and is limited by the arch of the first rib superiorly and the diaphragmatic insertion inferiorly. Tumors located at the upper part of the pulmonary sulcus near the thoracic inlet may correctly be regarded as superior sulcus tumors, although the inferior margins of the superior sulcus are not well defined.</p><p>The diagnosis and management of tumors arising within the superior sulcus are reviewed here. For patients with resectable disease, concurrent chemoradiotherapy is the recommended initial step in patient management (whereas in other cases of early-stage lung cancer, patients often proceed initially with surgery). Chemoradiotherapy is followed by surgical resection if there is no evidence of distant metastases or local progression. General issues regarding lung cancer and management of stage II and stage III non-small cell lung cancer are reviewed separately. (See  <a class="medical medical_review" href="/d/html/4641.html" rel="external">"Clinical manifestations of lung cancer"</a> and  <a class="medical medical_review" href="/d/html/4642.html" rel="external">"Management of stage I and stage II non-small cell lung cancer"</a> and  <a class="medical medical_review" href="/d/html/4623.html" rel="external">"Management of stage III non-small cell lung cancer"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Lesions in the superior sulcus may result in shoulder and arm pain (in the distribution of the C8, T1, and T2 dermatomes), Horner syndrome (ipsilateral ptosis, miosis, and anhidrosis; caused by injury to the sympathetic nerve chain), and weakness and atrophy of the muscles of the hand, a constellation of symptoms referred to as Pancoast syndrome or Pancoast-Tobias syndrome  (<a class="graphic graphic_figure graphicRef68096" href="/d/graphic/68096.html" rel="external">figure 2</a>) [<a href="#rid4">4</a>]. The majority of patients with superior sulcus tumors present with one or more of these complaints. Due to the peripheral location of the tumor, pulmonary symptoms such as cough, hemoptysis, and dyspnea are uncommon until late in the disease.</p><p class="headingAnchor" id="H3"><span class="h2">Shoulder pain</span><span class="headingEndMark"> — </span>The most common initial symptom of superior sulcus tumors is shoulder pain, present in 44 to 96 percent of patients [<a href="#rid5">5-11</a>]. Pain is produced by invasion of the brachial plexus and/or extension of the tumor into the parietal pleura, endothoracic fascia, first and second ribs, or vertebral bodies. Pain can progress and radiate up to the head and neck, or down to the medial aspect of the scapula, axilla, anterior chest, or ipsilateral arm in the distribution of the ulnar nerve [<a href="#rid10">10</a>].</p><p>Patients frequently receive treatment for presumed cervical osteoarthritis or shoulder bursitis, resulting in a delay in diagnosis of five to ten months in some series [<a href="#rid8">8,12-14</a>]. Pain ultimately becomes persistent and of such severity that the patient may need to support the involved arm with the uninvolved hand in order to obtain relief [<a href="#rid2">2,6,11</a>]. Adequate pain control measures are important when caring for patients with superior sulcus tumors. (See  <a class="medical medical_review" href="/d/html/2804.html" rel="external">"Overview of cancer pain syndromes", section on 'Plexopathies'</a> and  <a class="medical medical_review" href="/d/html/5266.html" rel="external">"Brachial plexus syndromes", section on 'Neoplastic and radiation-induced brachial plexopathy'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Horner syndrome</span><span class="headingEndMark"> — </span>Horner syndrome consists of ipsilateral ptosis with narrowing of the palpebral fissure, miosis, enophthalmos, and anhidrosis. It is caused by involvement of the paravertebral sympathetic chain and the inferior cervical (stellate) ganglion  (<a class="graphic graphic_figure graphicRef56089" href="/d/graphic/56089.html" rel="external">figure 3</a> and <a class="graphic graphic_picture graphicRef54798" href="/d/graphic/54798.html" rel="external">picture 1</a>). Its prevalence in patients with superior sulcus tumors has ranged from 14 to 83 percent in different series [<a href="#rid5">5,7,8,10,12,14-16</a>]. </p><p>Ipsilateral flushing and increased sweating of the face may occur before the development of the full Horner syndrome, presumably due to irritation of the sympathetic chain by the tumor prior to frank invasion [<a href="#rid4">4</a>]. Ipsilateral complex regional pain syndrome (reflex sympathetic dystrophy) and facial pain similar to paroxysmal hemicrania rarely may occur [<a href="#rid17">17,18</a>]. Contralateral facial sweating and flushing, especially with exercise, due to an excessive response by the intact sympathetic pathway have also been reported; this phenomenon is known as the Harlequin sign  (<a class="graphic graphic_picture graphicRef52477" href="/d/graphic/52477.html" rel="external">picture 2</a>) [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/d/html/5249.html" rel="external">"Horner syndrome"</a> and  <a class="medical medical_review" href="/d/html/5628.html" rel="external">"Complex regional pain syndrome in adults: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Neurologic complications involving the upper extremity</span><span class="headingEndMark"> — </span>Extension of tumor to the C8 and T1 nerve roots results in upper extremity neurologic findings in approximately 8 to 22 percent of cases [<a href="#rid4">4,10</a>]. Involvement of these nerve roots may result in weakness and atrophy of the intrinsic muscles of the hand, or pain and paresthesia of the fourth and fifth digits and the medial aspect of the arm and forearm. Abnormal sensation and pain in the T2 territory (the axilla and medial aspect of the upper arm) may also be an early finding, and the triceps reflex may be lost [<a href="#rid20">20</a>]. </p><p>Superior sulcus tumors invade the intervertebral foramina early in the course of disease in approximately 5 percent of patients and may cause spinal cord compression and paraplegia [<a href="#rid4">4</a>]. Approximately 25 percent of patients ultimately develop spinal cord compression. (See  <a class="medical medical_review" href="/d/html/2819.html" rel="external">"Clinical features and diagnosis of neoplastic epidural spinal cord compression"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Other findings</span><span class="headingEndMark"> — </span>Supraclavicular lymph node enlargement and prominent weight loss are each observed in approximately 25 to 35 percent of cases [<a href="#rid4">4,10</a>]. Superior sulcus tumors may produce a phrenic or recurrent laryngeal neuropathy or superior vena cava syndrome in 5 to 10 percent of patients [<a href="#rid4">4,10</a>]. (See  <a class="medical medical_review" href="/d/html/2832.html" rel="external">"Malignancy-related superior vena cava syndrome"</a>.) </p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS AND PATHOLOGY</span><span class="headingEndMark"> — </span>A histologic diagnosis is mandatory prior to definitive treatment because of the wide variety of malignancies and benign pathologic processes that can produce Pancoast syndrome.</p><p class="headingAnchor" id="H445181737"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Core needle biopsy is generally preferred to provide tissue for histology and molecular markers. The location of superior sulcus tumors allows the majority to be diagnosed by percutaneous needle biopsy. This technique can be performed via a posterior or cervical approach with the use of biplane fluoroscopy, ultrasonography, or computed tomography to localize the lesion. Diagnostic yields of more than 90 percent are reported [<a href="#rid15">15,21,22</a>]. Video-assisted thoracoscopy (VATS) or thoracotomy can be performed if less invasive techniques are nondiagnostic. </p><p>By contrast, the peripheral location of superior sulcus tumors decreases the diagnostic yield of bronchoscopy and is therefore less useful for diagnostic purposes for superior sulcus tumors. Fiberoptic bronchoscopy with cytology and biopsies provides a diagnosis in 30 to 40 percent of cases, but unexpected endobronchial tumors may occasionally be detected, significantly altering therapeutic decisions [<a href="#rid8">8,14,23</a>]. </p><p class="headingAnchor" id="H445181834"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>The overwhelming majority of superior sulcus tumors are non-small cell lung cancers (NSCLCs), and in the past were mainly squamous cell carcinomas [<a href="#rid2">2,8,15,24-27</a>], although in subsequent series adenocarcinomas predominate [<a href="#rid28">28-30</a>]. Although NSCLC predominates as the cause of superior sulcus tumors, less than 5 percent of all NSCLCs arise in this region [<a href="#rid5">5,24</a>]. Small cell carcinomas account for up to 5 percent of cases in most series [<a href="#rid5">5,9,28,31-33</a>]. </p><p>Broad molecular testing for epidermal growth factor receptor (<em>EGFR</em>) mutations, anaplastic lymphoma kinase (<em>ALK</em>) rearrangement, c-ROS oncogene 1 (<em>ROS1</em>) rearrangement, programmed cell death receptor 1 (PD-1) expression, and other targetable mutations in nonsquamous NSCLC should be performed for patients who have stage IV disease, are not candidates for definitive local therapies, or for those who recur after definitive local treatment. In recurrent tumors, this testing is ideally carried out on tissue obtained at the time of recurrence [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer"</a>.)</p><p class="headingAnchor" id="H2613776504"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>A variety of rarer lesions other than lung cancer can arise in the superior sulcus and cause Pancoast syndrome. The differential diagnosis of superior sulcus mass lesions includes adenoid cystic carcinoma, hemangiopericytoma, mesothelioma, lymphoma, plasmacytoma, and metastatic malignancies from the cervix, larynx, liver, bladder, and thyroid gland [<a href="#rid35">35-43</a>]. Lymphomatoid granulomatosis, vascular aneurysms, amyloid nodules, cervical rib syndrome, and various infections (eg, tuberculosis, fungi, hydatid cysts, sequelae of bacterial pneumonia) can also result in Pancoast syndrome [<a href="#rid44">44-58</a>]. </p><p class="headingAnchor" id="H445182062"><span class="h1">STAGING</span><span class="headingEndMark"> — </span>Superior sulcus tumors are staged in the same way as non-small cell lung cancers (NSCLCs) located elsewhere in the thorax  (<a class="graphic graphic_figure graphicRef73945" href="/d/graphic/73945.html" rel="external">figure 4</a>). The eighth edition of the tumor, node, metastasis (TNM) system is used to stage primary lung tumors  (<a class="graphic graphic_table graphicRef109805" href="/d/graphic/109805.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef109806" href="/d/graphic/109806.html" rel="external">table 2</a>). Superior pulmonary sulcus tumors are typically T3 or T4 lesions, depending on whether the tumor extends only as far as the chest wall or invades the brachial plexus, mediastinal structures, or vertebral bodies. In the absence of metastases to scalene nodes, supraclavicular nodes, contralateral mediastinal nodes  (<a class="graphic graphic_figure graphicRef73945" href="/d/graphic/73945.html" rel="external">figure 4</a>), or distant sites, the tumors usually fall into the category of stage IIB (T3,N0), IIIA (T3,N1, or T4, N0-1), or IIIB (T3-4,N2) disease, classified according to the American Joint Committee on Cancer/Union for International Cancer Control eighth edition TNM staging system. (See  <a class="medical medical_review" href="/d/html/4632.html" rel="external">"Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer"</a> and  <a class="medical medical_review" href="/d/html/4602.html" rel="external">"Tumor, node, metastasis (TNM) staging system for lung cancer"</a>.)</p><p class="headingAnchor" id="H445181639"><span class="h1">PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>Accurate staging of superior sulcus tumors is critical so that optimal therapy may be provided and unnecessary treatment-related morbidity can be avoided. As in other situations, preoperative evaluation should be performed to determine the patient's ability to tolerate resection based on cardiovascular and pulmonary risk stratification and should include a shared decision-making discussion with patient about risks and benefits. (See  <a class="medical medical_review" href="/d/html/6973.html" rel="external">"Preoperative physiologic pulmonary evaluation for lung resection"</a> and  <a class="medical medical_review" href="/d/html/6616.html" rel="external">"Evaluation of cardiac risk prior to noncardiac surgery"</a>.)</p><p>Metastatic spread to the mediastinum or distant sites should be diligently sought by history, physical examination, blood tests, and imaging. Computed tomography (CT) of the chest and upper abdomen should be performed to evaluate the mediastinum, liver, and adrenal glands for possible metastatic foci. Positron emission tomography (PET) scanning is necessary for preoperative evaluation of mediastinal lymph nodes as well as distant metastases. (See  <a class="medical medical_review" href="/d/html/4632.html" rel="external">"Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer"</a> and  <a class="medical medical_review" href="/d/html/4602.html" rel="external">"Tumor, node, metastasis (TNM) staging system for lung cancer"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Initial imaging</span><span class="headingEndMark"> — </span>Radiographic findings of superior sulcus tumors include a unilateral apical cap of more than 5 mm, asymmetry of bilateral apical caps of more than 5 mm, an apical mass, and bone destruction [<a href="#rid8">8,11,59</a>]. Lordotic chest views and upper thoracic and lower cervical spine radiographs may be helpful in the visualization of the tumor  (<a class="graphic graphic_diagnosticimage graphicRef67213" href="/d/graphic/67213.html" rel="external">image 1</a>).</p><p>CT of the chest provides additional information about a superior sulcus tumor and its extension, including the presence of satellite pulmonary nodules, parenchymal disease, and hilar or mediastinal lymphadenopathy  (<a class="graphic graphic_diagnosticimage graphicRef78372" href="/d/graphic/78372.html" rel="external">image 2</a>) [<a href="#rid59">59-62</a>]. CT is limited, however, in the evaluation of brachial plexus, subclavian vessel, and chest wall involvement. </p><p>Although the comparative value of magnetic resonance imaging (MRI) over CT for detection of chest wall invasion is not clearly established, many studies suggest that MRI is more accurate [<a href="#rid61">61-68</a>]. MRI is especially useful in documenting the extent of involvement of the brachial plexus and subclavian vessels, and evaluating vertebral bodies and the spinal canal for tumor extension  (<a class="graphic graphic_diagnosticimage graphicRef56298 graphicRef64987 graphicRef75753" href="/d/graphic/56298.html" rel="external">image 3A-C</a>). A magnetic resonance angiogram may be useful for detecting vascular involvement of the subclavian artery [<a href="#rid69">69</a>].</p><p>Although some studies have suggested that MRI is superior to CT in the detection of mediastinal lymph node involvement, the accuracy of these two methods is generally similar [<a href="#rid70">70,71</a>]. Studies evaluating the efficacy of CT staging of mediastinal lymph node metastases for non-Pancoast NSCLC have reported sensitivity and specificity of 60 to 70 percent. fluorodeoxyglucose PET-CT is more accurate for mediastinal lymph node evaluation than CT alone. (See  <a class="medical medical_review" href="/d/html/6976.html" rel="external">"Magnetic resonance imaging of the thorax"</a> and  <a class="medical medical_review" href="/d/html/4632.html" rel="external">"Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer"</a> and  <a class="medical medical_review" href="/d/html/4602.html" rel="external">"Tumor, node, metastasis (TNM) staging system for lung cancer"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Mediastinal evaluation</span><span class="headingEndMark"> — </span>CT and MRI cannot definitively establish the presence or absence of mediastinal invasion or nodal metastasis [<a href="#rid72">72-74</a>], and surgical staging of the mediastinum should generally be undertaken prior to attempts at curative surgery. </p><p>Although a negative PET scan appears highly accurate in predicting an uninvolved mediastinum, surgical staging of the mediastinum prior to definitive treatment is generally considered the standard of care. PET scanning may also be the most sensitive test for identifying the presence of distant metastases in liver, adrenal gland and other lymph nodes. PET scans are routinely performed as a component of the staging evaluation.</p><p>Endobronchial ultrasound (EBUS) is a useful tool for establishing mediastinal metastasis, especially with enlarged or PET positive lymph nodes in the mediastinum. Establishing N2 or N3 metastases by EBUS precludes the need for mediastinoscopy. (See  <a class="medical medical_review" href="/d/html/4386.html" rel="external">"Endobronchial ultrasound: Indications, contraindications, and complications"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Brain imaging</span><span class="headingEndMark"> — </span>MRI or CT scans of the brain provide complementary staging information. We recommend routine preoperative brain imaging with MRI (CT if the patient cannot undergo MRI) for superior sulcus tumors because of the high propensity for brain metastasis from bronchogenic carcinoma in this location [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/d/html/4632.html" rel="external">"Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer"</a> and  <a class="medical medical_review" href="/d/html/4602.html" rel="external">"Tumor, node, metastasis (TNM) staging system for lung cancer"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>For patients with resectable disease, concurrent chemoradiotherapy is the recommended initial step in patient management. This is followed by surgical resection if there is no evidence of distant metastases or local progression and postoperative chemotherapy. Adjuvant <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> is now used for patients with stage II to IIIA non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) expression of 1 percent or greater [<a href="#rid76">76</a>], and adjuvant <a class="drug drug_general" data-topicid="105441" href="/d/drug information/105441.html" rel="external">osimertinib</a> is offered for patients with resected epidermal growth factor receptor (EGFR)-positive NSCLC [<a href="#rid77">77</a>]. </p><p class="headingAnchor" id="H18"><span class="h2">Induction chemoradiotherapy plus surgery</span><span class="headingEndMark"> — </span>In patients with locally advanced, stage III NSCLC, randomized trials have demonstrated that induction chemotherapy followed by definitive radiation therapy (RT) improves survival compared to RT alone. Further studies showed that concurrent chemotherapy plus RT provides an additional survival advantage over sequential treatment. The success of these approaches in the treatment of non-Pancoast, locally advanced, stage III NSCLC has led to their use in patients with superior sulcus tumors and defined the standard of care for these tumors. (See  <a class="medical medical_review" href="/d/html/4623.html" rel="external">"Management of stage III non-small cell lung cancer"</a>.)</p><p>Although there are no randomized trials comparing induction chemoradiotherapy with preoperative RT or surgery alone specifically for patients with superior sulcus tumors, several studies have focused on this approach in this setting. The potential value of this is illustrated by the following results:</p><p class="bulletIndent1"><span class="glyph">●</span>A best-evidence analysis of the literature concluded that induction chemoradiotherapy followed by surgery resulted in superior survival compared with radiotherapy followed by surgery or surgery alone for patients with superior sulcus tumors [<a href="#rid78">78</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The largest prospective study was conducted in North America as a cooperative intergroup study in 111 patients, and evaluated concurrent chemotherapy (two cycles of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>) and thoracic RT (45 Gy in 25 fractions) followed by resection three to five weeks later, and two additional cycles of postoperative chemotherapy [<a href="#rid79">79</a>]. Eligible patients had pathologically proven T3-4, N0-1 NSCLC presenting in the superior sulcus, and all underwent staging mediastinoscopy. Patients with positive N2 lymph node metastases were excluded from the study.</p><p></p><p class="bulletIndent1">Mature results from this study found that 80 percent of patients underwent thoracotomy and 76 percent had a complete (R0) resection of tumor [<a href="#rid80">80</a>]. The overall five-year survival rate for the entire series was 44 percent. Patients with a complete pathologic response at resection had a significantly better prognosis than those with either microscopic or gross residual disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar results were seen in a Japanese study that utilized two cycles of chemotherapy with <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a>, <a class="drug drug_general" data-topicid="10303" href="/d/drug information/10303.html" rel="external">vindesine</a>, and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> concurrent with split-course RT (45 Gy in 25 daily fractions). This was followed by surgery two to four weeks after completion of induction therapy [<a href="#rid81">81</a>]. There were three treatment-related deaths. Of the 76 enrolled patients, 57 underwent surgery (76 percent), of whom 51 (68 percent) had a complete (R0) resection. There were 12 complete pathologic responses. The disease-free and overall survival rates at five years were 45 and 56 percent, respectively. Systemic recurrence was the main reason for death in both trials, reported in approximately 80 percent of patients who recurred. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A single institution study from France enrolled 107 patients with Pancoast tumors and treated with induction chemoradiotherapy (<a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>). Patients with bulky N2 and N3 disease were excluded. Of these, 72 had a thoracotomy and all but one had macroscopic complete resections. There were 21 pneumonectomies performed, and four patients died of surgical complications. A pathological complete response or microscopic residual disease was observed in 40 percent of all surgical participants. After induction therapy, 61 percent of pathological N2 positive participants (28 of 46) were downstaged to pN0/N1. Overall survival for the entire cohort was 55 and 40 percent at two and three years, respectively, with a median survival time of 26.7 months [<a href="#rid82">82</a>].</p><p></p><p>Although a randomized trial comparing induction chemoradiotherapy with preoperative RT or surgery alone has not been conducted, a retrospective review of 35 patients from a single institution found that concurrent chemoradiotherapy with a cisplatin-based regimen followed by surgery resulted in improved survival rates (93 versus 49 percent at two years and 84 versus 49 percent at four years, compared to induction RT followed by surgery) [<a href="#rid83">83</a>]. There was also a higher rate of complete or near complete pathologic response with concurrent chemoradiotherapy (13 of 15 [87 percent] versus 7 of 20 [35 percent]).</p><p>Similarly, another center utilizing a trimodality approach for Pancoast tumors observed a pathologic complete response of 40 percent in 36 patients [<a href="#rid84">84</a>]. The overall median survival was 2.6 years in all patients and eight years for those with a pathologic complete response.</p><p>These results are better than those obtained with either preoperative RT or surgery alone. As a result, induction chemoradiotherapy followed by surgery has been adopted by most centers as the standard treatment for Pancoast tumors without distant or mediastinal metastases.  </p><p class="headingAnchor" id="H2004624224"><span class="h2">Choice of regimen</span><span class="headingEndMark"> — </span>Although the optimal regimen has not been established, a reasonable choice is that used in the North America Intergroup study [<a href="#rid79">79</a>]:  </p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent thoracic RT (45 Gy over five weeks in daily 1.8 Gy fractions) and chemotherapy, consisting of two cycles of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (50 mg/m<sup>2</sup> on days 1, 8, 29, and 36) and <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> (50 mg/m<sup>2</sup> on days 1 to 5 and 29 to 33). Some clinicians have advocated increasing the thoracic RT dose to 60 to 66 Gy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thoracotomy for tumor resection three to five weeks after completion of chemoradiotherapy, if there is no evidence of distant metastases or local progression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two additional postoperative courses of chemotherapy with a platinum-based doublet. (See  <a class="medical medical_review" href="/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation", section on 'Preference for platinum-based regimens'</a>.)  </p><p></p><p>Based upon the favorable results of the phase II study (SWOG 9504) with consolidation <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> after definitive chemoradiotherapy in patients with stage III NSCLC, the lung intergroup completed a trial (SWOG-S0220) in patients with Pancoast tumor, but found that consolidation chemotherapy with single-agent docetaxel following surgery was not feasible [<a href="#rid85">85</a>]. Of note, the phase III confirmatory trial demonstrated that consolidation docetaxel after definitive chemoradiotherapy did not lead to improved survival and resulted in increased toxicities [<a href="#rid86">86</a>]. (See  <a class="medical medical_review" href="/d/html/4623.html" rel="external">"Management of stage III non-small cell lung cancer", section on 'Preferred approach: Chemoradiotherapy, followed by durvalumab'</a>.)</p><p>Incorporation of immunotherapy into neoadjuvant regimens for locally or locoregionally advanced NSCLC is discussed elsewhere, although this is not a standard approach at this time . (See  <a class="medical medical_review" href="/d/html/4636.html" rel="external">"Systemic therapy in resectable non-small cell lung cancer", section on 'Patients receiving neoadjuvant treatment'</a>.)</p><p class="headingAnchor" id="H528222775"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>Surgery is generally undertaken three to five weeks after the completion of chemoradiotherapy. This is typically carried out through en bloc resection of the tumor and the chest wall, and, depending upon the extent of local invasion, may require resection of the paravertebral sympathetic chain, stellate ganglion, lower trunks of the brachial plexus, subclavian artery, or portions of the thoracic vertebrae. One of two surgical approaches may be utilized:</p><p class="bulletIndent1"><span class="glyph">●</span>The posterior approach, also termed the Paulson operation, is performed via a long incision along the medial edge of the scapula starting between the second or third thoracic vertebra and the scapula, extending underneath its inferior tip, and ending at the anterior axillary line [<a href="#rid2">2,87,88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The anterior transcervical approach involves a long L-shaped incision that extends from the mandibular angle along the anterior border of the sternocleidomastoid muscle down to the suprasternal notch and laterally under the medial half of the clavicle [<a href="#rid87">87,89,90</a>]. This technique is generally used for tumors located anteriorly at the thoracic inlet, particularly those invading the subclavian vessels. A variation of this approach, the anterior "hemi-clamshell" incision, permits sparing of the clavicle [<a href="#rid91">91-93</a>].</p><p></p><p>The extent of lung resection is determined by the size and location of the primary tumor and the patient's underlying pulmonary function. Lobectomy is generally considered the preferable procedure for lung cancers, with fewer local recurrences and better survival when compared with sublobar resections [<a href="#rid26">26,87,94</a>].</p><p>A combined thoracic-neurosurgical approach is necessary in treating tumors that invade the brachial plexus and/or the spine [<a href="#rid16">16,95-98</a>]. Recent advances in spinal instrumentation have allowed more complete resection of tumors involving the vertebral body [<a href="#rid96">96-98</a>]. Surgery is contraindicated by extensive invasion of the brachial plexus, the intervertebral foramina, or soft tissues at the base of the neck; by mediastinal perinodal involvement; and by venous obstruction [<a href="#rid2">2,6,11,14,99</a>]. Involvement of the vertebral bodies, subclavian artery, and spread to the ipsilateral supraclavicular lymph nodes are relative, but not absolute contraindications in the opinion of some authors [<a href="#rid74">74,89,97</a>].</p><p class="headingAnchor" id="H528222782"><span class="h3">Complications</span><span class="headingEndMark"> — </span>In addition to the standard potential complications of lung resection, extirpation of superior sulcus tumors may result in chylothorax, ulnar nerve paralysis secondary to resection of the C8 nerve root, Horner syndrome (if not present preoperatively) due to resection of the stellate ganglion and the sympathetic chain, or a cerebrospinal fluid leak and meningitis. Resection of T1 and T2 nerve roots generally does not result in major clinical sequelae. Reported surgical mortality rates are approximately 4 to 10 percent [<a href="#rid100">100,101</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Chemoradiotherapy or RT alone without surgery</span><span class="headingEndMark"> — </span>Patients with locally advanced, unresectable (eg, N2, N3) disease and those who are medically inoperable but fit enough to receive chemotherapy should be offered chemoradiotherapy. In the setting of non-Pancoast stage III NSCLC, concurrent chemoradiotherapy has been shown to be superior to radiation therapy (RT) alone and has become the standard of care. Adjuvant immunotherapy with <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a> for one year after definitive chemoradiotherapy has become the standard for stage III NSCLC. (See  <a class="medical medical_review" href="/d/html/4623.html" rel="external">"Management of stage III non-small cell lung cancer", section on 'Preferred approach: Chemoradiotherapy, followed by durvalumab'</a>.)</p><p>RT as a sole primary treatment modality is suitable for patients with metastatic tumors or poor performance status  (<a class="graphic graphic_table graphicRef109805" href="/d/graphic/109805.html" rel="external">table 1</a>), providing palliation of pain in up to 90 percent of patients [<a href="#rid5">5,9,102</a>]. A dose of 60 to 66 Gy is generally recommended for definitive treatment of unresectable disease [<a href="#rid11">11,28,103</a>]. However a lower dose (eg, 30 Gy) is reasonable for palliation in those with distant metastases. </p><p>Five-year survival rates up to 40 percent have been reported for selected patients treated definitively with radical RT for localized superior sulcus tumors [<a href="#rid5">5,9,103,104</a>]. However, it is difficult to compare results with RT alone to those obtained with combined modality therapy, since many studies of primary RT have included patients with unfavorable prognostic factors and unresectable tumors [<a href="#rid103">103</a>]. Furthermore, many series include patients treated before the era of imaging with CT and/or magnetic resonance imaging, who were thus less adequately staged.  </p><p>While resection is generally accepted as a component of treatment for locally advanced NSCLC, its value is uncertain in patients with stage IIIA (N2) disease  (<a class="graphic graphic_table graphicRef109805" href="/d/graphic/109805.html" rel="external">table 1</a>). Interim reports of the major randomized prospective study addressing the value of resection when added to chemoradiotherapy have failed to demonstrate a statistically significant survival advantage for the addition of resection to chemoradiotherapy for locally advanced non-Pancoast NSCLC [<a href="#rid105">105</a>]. (See  <a class="medical medical_review" href="/d/html/4623.html" rel="external">"Management of stage III non-small cell lung cancer", section on 'No clinical mediastinal involvement prior to surgery'</a>.)</p><p>Common side effects of RT include fatigue, esophagitis, localized lung fibrosis, and skin irritation. Less commonly patients develop symptomatic pneumonitis. Rare complications include skin fibrosis with shoulder immobility; myelitis and brachial neuritis may result in weakness and pain in the hand, arm, or shoulder [<a href="#rid5">5,106</a>]. (See  <a class="medical medical_review" href="/d/html/4331.html" rel="external">"Radiation-induced lung injury"</a> and  <a class="medical medical_review" href="/d/html/5266.html" rel="external">"Brachial plexus syndromes", section on 'Neoplastic and radiation-induced brachial plexopathy'</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">PROGNOSTIC FACTORS</span><span class="headingEndMark"> — </span>In addition to tumor stage, several clinical and histologic features are prognostically important in patients with superior sulcus tumors. The presence of Horner syndrome, extension of the tumor into the base of the neck, vertebral bodies or the great vessels, or involvement of the mediastinal lymph nodes is associated with a worse prognosis [<a href="#rid104">104,107</a>]. Longer duration of symptoms has also been found to adversely affect the prognosis, probably because of an association with more advanced disease [<a href="#rid14">14</a>].</p><p>A good performance status  (<a class="graphic graphic_table graphicRef58785" href="/d/graphic/58785.html" rel="external">table 3</a>) and weight loss of no more than 5 percent of total body weight are associated with better survival [<a href="#rid10">10,28</a>]. Local control of the tumor by radiation and/or surgery as well as the achievement of pain relief after treatment are encouraging and suggest a better prognosis. Most studies have not found an association between histologic subtype and survival.</p><p>A pathologic complete response after induction chemoradiotherapy has generally been correlated with better survival. A study from the Netherlands performed fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) before and after induction therapy. Changes in standardized uptake values (SUV) were predictive of an excellent pathologic response (≤10 percent viable cells) and correlated with residual tumor cells [<a href="#rid108">108</a>].</p><p class="headingAnchor" id="H22"><span class="h1">POST-THERAPY SURVEILLANCE</span><span class="headingEndMark"> — </span>The evidence from these studies does not establish a clear-cut benefit for aggressive surveillance following treatment with curative intent. Guidelines from the American Society of Clinical Oncology [<a href="#rid109">109</a>] and the National Comprehensive Cancer Network [<a href="#rid110">110</a>] differ in their use of imaging studies. We suggest a history, physical examination, and computed tomography of the chest every three to six months for the first three years, then every six months for two years and annually thereafter. (See  <a class="medical medical_review" href="/d/html/4642.html" rel="external">"Management of stage I and stage II non-small cell lung cancer", section on 'Post-therapy surveillance'</a> and  <a class="medical medical_review" href="/d/html/14613.html" rel="external">"Radiation-related risks of imaging"</a>.)</p><p class="headingAnchor" id="H1501614044"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112231.html" rel="external">"Society guideline links: Diagnosis and management of lung cancer"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span>Superior sulcus tumors are characterized by a distinct constellation of presenting signs and symptoms due to their location. Most of these tumors are non-small cell lung cancers (NSCLCs). (See <a class="local">'Clinical manifestations'</a> above and <a class="local">'Diagnosis and pathology'</a> above.)</p><p>The management of Pancoast tumors is similar to that of other locally advanced NSCLCs:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with no distant metastatic disease, we recommend concurrent chemoradiotherapy as the initial step in patient management (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). This is followed by surgical resection if there is no evidence of distant metastases or local progression (N2 or N3) (see <a class="local">'Induction chemoradiotherapy plus surgery'</a> above). Although the optimal regimen has not been established, a reasonable choice is that used in the North America Intergroup study:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Concurrent thoracic radiotherapy (RT) (45 Gy over five weeks in daily 1.8 Gy fractions) and chemotherapy, consisting of two cycles of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> (50 mg/m<sup>2</sup> on days 1, 8, 29, and 36) and <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> (50 mg/m<sup>2</sup> on days 1 to 5, and 29 to 33). Some clinicians have advocated increasing the thoracic radiotherapy dose to 60 to 66 Gy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tumor resection in patients without N2 metastases, three to five weeks after completion of chemoradiotherapy, if there is no evidence of distant metastases or local progression.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two additional postoperative courses of chemotherapy, with a platinum-based chemotherapy doublet if the patient's physical status permits.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who undergo surgical resection, adjuvant <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> (for those with stage II to IIIA NSCLC and programmed cell death ligand 1 expression ≥1 percent) or <a class="drug drug_general" data-topicid="105441" href="/d/drug information/105441.html" rel="external">osimertinib</a> (for those with resected epidermal growth factor receptor (<em>EGFR</em>)-mutant disease) are offered, as discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/4636.html" rel="external">"Systemic therapy in resectable non-small cell lung cancer", section on 'Adjuvant immunotherapy'</a> and  <a class="medical medical_review" href="/d/html/4636.html" rel="external">"Systemic therapy in resectable non-small cell lung cancer", section on 'EGFR-mutated cancers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are medically inoperable or who have locally advanced, unresectable disease, we recommend definitive chemoradiotherapy and adjuvant immunotherapy with <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a> for one year. (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>).  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have distant metastatic disease or a poor performance status, RT can be used to treat symptoms due to the Pancoast tumor. For patients with locally advanced or metastatic disease, systemic therapy may be useful to palliate symptoms and extend survival duration. (See <a class="local">'Chemoradiotherapy or RT alone without surgery'</a> above and  <a class="medical medical_review" href="/d/html/4607.html" rel="external">"Overview of the initial treatment of advanced non-small cell lung cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Whenever possible, patients with superior sulcus tumors should be enrolled in prospective clinical trials so that the optimal therapy may be determined.</p><p></p><p class="headingAnchor" id="H4274030424"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges James R Jett, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pancoast, HK. Superior pulmonary sulcus tumor. JAMA 1932; 99:1391.</a></li><li><a class="nounderline abstract_t">Paulson DL. Carcinomas in the superior pulmonary sulcus. J Thorac Cardiovasc Surg 1975; 70:1095.</a></li><li><a class="nounderline abstract_t">Teixeira JP. Concerning the Pancoast tumor: what is the superior pulmonary sulcus? Ann Thorac Surg 1983; 35:577.</a></li><li><a class="nounderline abstract_t">Arcasoy SM, Jett JR. Superior pulmonary sulcus tumors and Pancoast's syndrome. N Engl J Med 1997; 337:1370.</a></li><li><a class="nounderline abstract_t">Van Houtte P, MacLennan I, Poulter C, Rubin P. External radiation in the management of superior sulcus tumor. Cancer 1984; 54:223.</a></li><li><a class="nounderline abstract_t">Urschel HC Jr. Superior pulmonary sulcus carcinoma. Surg Clin North Am 1988; 68:497.</a></li><li><a class="nounderline abstract_t">Shahian DM, Neptune WB, Ellis FH Jr. Pancoast tumors: improved survival with preoperative and postoperative radiotherapy. Ann Thorac Surg 1987; 43:32.</a></li><li><a class="nounderline abstract_t">Miller JI, Mansour KA, Hatcher CR Jr. Carcinoma of the superior pulmonary sulcus. Ann Thorac Surg 1979; 28:44.</a></li><li><a class="nounderline abstract_t">Komaki R, Roh J, Cox JD, Lopes da Conceicao A. Superior sulcus tumors: results of irradiation of 36 patients. Cancer 1981; 48:1563.</a></li><li><a class="nounderline abstract_t">Komaki, R. Preoperative radiation therapy for superior sulcus lesions. Chest Surg Clin North Am 1991; 1:13.</a></li><li class="breakAll">Grover FL, Komaki R. Superior sulcus tumors. In: Thoracic Oncology, 2nd ed, Roth JA, Ruckdeschel JC, Weisenburger TH (Eds), WB Saunders, Philadelphia 1995. p.225.</li><li><a class="nounderline abstract_t">Hepper NG, Herskovic T, Witten DM, et al. Thoracic inlet tumors. Ann Intern Med 1966; 64:979.</a></li><li><a class="nounderline abstract_t">Ziporyn T. Upper body pain: possible tipoff to Pancoast tumor. JAMA 1981; 246:1759, 1763.</a></li><li><a class="nounderline abstract_t">Anderson TM, Moy PM, Holmes EC. Factors affecting survival in superior sulcus tumors. J Clin Oncol 1986; 4:1598.</a></li><li><a class="nounderline abstract_t">Walls WJ, Thornbury JR, Naylor B. Pulmonary needle aspiration biopsy in the diagnosis of Pancoast tumors. Radiology 1974; 111:99.</a></li><li><a class="nounderline abstract_t">Sundaresan N, Hilaris BS, Martini N. The combined neurosurgical-thoracic management of superior sulcus tumors. J Clin Oncol 1987; 5:1739.</a></li><li><a class="nounderline abstract_t">Derbekyan V, Novales-Diaz J, Lisbona R. Pancoast tumor as a cause of reflex sympathetic dystrophy. J Nucl Med 1993; 34:1992.</a></li><li><a class="nounderline abstract_t">Delreux V, Kevers L, Callewaert A. [Paroxysmal hemicrania preceding Pancoast's syndrome]. Rev Neurol (Paris) 1989; 145:151.</a></li><li><a class="nounderline abstract_t">Umeki S, Tamai H, Yagi S, et al. [Harlequin syndrome (unilateral flushing and sweating attack) due to a spinal invasion of the left apical lung cancer]. Rinsho Shinkeigaku 1990; 30:94.</a></li><li><a class="nounderline abstract_t">Marangoni C, Lacerenza M, Formaglio F, et al. Sensory disorder of the chest as presenting symptom of lung cancer. J Neurol Neurosurg Psychiatry 1993; 56:1033.</a></li><li><a class="nounderline abstract_t">Paulson DL, Weed TE, Rian RL. Cervical approach for percutaneous needle biopsy of Pancoast tumors. Ann Thorac Surg 1985; 39:586.</a></li><li><a class="nounderline abstract_t">Yang PC, Lee LN, Luh KT, et al. Ultrasonography of Pancoast tumor. Chest 1988; 94:124.</a></li><li><a class="nounderline abstract_t">Maxfield RA, Aranda CP. The role of fiberoptic bronchoscopy and transbronchial biopsy in the diagnosis of Pancoast's tumor. N Y State J Med 1987; 87:326.</a></li><li class="breakAll">Ginsberg RJ, Payne DG, Shamji F. Superior sulcus tumors. In: Comprehensive Textbook of Thoracic Oncology, Aisner J (Ed), Williams &amp; Wilkins, Baltimore 1996. p.375.</li><li><a class="nounderline abstract_t">Fuller DB, Chambers JS. Superior sulcus tumors: combined modality. Ann Thorac Surg 1994; 57:1133.</a></li><li><a class="nounderline abstract_t">Hilaris BS, Martini N, Wong GY, Nori D. Treatment of superior sulcus tumor (Pancoast tumor). Surg Clin North Am 1987; 67:965.</a></li><li><a class="nounderline abstract_t">Devine JW, Mendenhall WM, Million RR, Carmichael MJ. Carcinoma of the superior pulmonary sulcus treated with surgery and/or radiation therapy. Cancer 1986; 57:941.</a></li><li><a class="nounderline abstract_t">Komaki R, Mountain CF, Holbert JM, et al. Superior sulcus tumors: treatment selection and results for 85 patients without metastasis (Mo) at presentation. Int J Radiat Oncol Biol Phys 1990; 19:31.</a></li><li><a class="nounderline abstract_t">Jones DR, Detterbeck FC. Pancoast tumors of the lung. Curr Opin Pulm Med 1998; 4:191.</a></li><li><a class="nounderline abstract_t">Gomez DR, Cox JD, Roth JA, et al. A prospective phase 2 study of surgery followed by chemotherapy and radiation for superior sulcus tumors. Cancer 2012; 118:444.</a></li><li><a class="nounderline abstract_t">Maggi G, Casadio C, Pischedda F, et al. Combined radiosurgical treatment of Pancoast tumor. Ann Thorac Surg 1994; 57:198.</a></li><li><a class="nounderline abstract_t">Johnson DH, Hainsworth JD, Greco FA. Pancoast's syndrome and small cell lung cancer. Chest 1982; 82:602.</a></li><li><a class="nounderline abstract_t">Robinson LA, Tanvetyanon T, Grubbs D, et al. Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer. Lung Cancer 2018; 122:206.</a></li><li class="breakAll">International Association for the Study of Lung Cancer. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors. Summary of recommendations. http://www.iaslc.org/Portals/0/26328_testinglung%20cancerl_Summary%201_18_18_AMP%20linked.pdf?ver=2019-05-28-223919-880 (Accessed on February 18, 2020).</li><li><a class="nounderline abstract_t">Hatton MQ, Allen MB, Cooke NJ. Pancoast syndrome: an unusual presentation of adenoid cystic carcinoma. Eur Respir J 1993; 6:271.</a></li><li><a class="nounderline abstract_t">Chong KM, Hennox SC, Sheppard MN. Primary hemangiopericytoma presenting as a Pancoast tumor. Ann Thorac Surg 1993; 55:9.</a></li><li><a class="nounderline abstract_t">Amin R. Bilateral Pancoast's syndrome in a patient with carcinoma of the cervix. Gynecol Oncol 1986; 24:126.</a></li><li><a class="nounderline abstract_t">Chang CF, Su WJ, Chou TY, Perng RP. Hepatocellular carcinoma with Pancoast's syndrome as an initial symptom: a case report. Jpn J Clin Oncol 2001; 31:119.</a></li><li><a class="nounderline abstract_t">Rabano A, La Sala M, Hernandez P, Barros JL. Thyroid carcinoma presenting as Pancoast's syndrome. Thorax 1991; 46:270.</a></li><li><a class="nounderline abstract_t">Brenner B, Carter A, Freidin N, et al. Pancoast's syndrome in multiple myeloma. Acta Haematol 1984; 71:353.</a></li><li><a class="nounderline abstract_t">Chen KT, Padmanabhan A. Pancoast syndrome caused by extramedullary plasmacytoma. J Surg Oncol 1983; 24:117.</a></li><li><a class="nounderline abstract_t">Mills PR, Han LY, Dick R, Clarke SW. Pancoast syndrome caused by a high grade B cell lymphoma. Thorax 1994; 49:92.</a></li><li><a class="nounderline abstract_t">Arcasoy SM, Bajwa MK, Jett JR. Non-Hodgkin's lymphoma presenting as Pancoast's syndrome. Respir Med 1997; 91:571.</a></li><li><a class="nounderline abstract_t">White HD, White BA, Boethel C, Arroliga AC. Pancoast's syndrome secondary to infectious etiologies: a not so uncommon occurrence. Am J Med Sci 2011; 341:333.</a></li><li><a class="nounderline abstract_t">Dolan G, Smith J, Reilly JT. Extrapulmonary lymphomatoid granulomatosis presenting as Pancoast's syndrome. Postgrad Med J 1991; 67:914.</a></li><li><a class="nounderline abstract_t">Vandenplas O, Mercenier C, Trigaux JP, Delaunois L. Pancoast's syndrome due to Pseudomonas aeruginosa infection of the lung apex. Thorax 1991; 46:683.</a></li><li><a class="nounderline abstract_t">Gallagher KJ, Jeffrey RR, Kerr KM, Steven MM. Pancoast syndrome: an unusual complication of pulmonary infection by Staphylococcus aureus. Ann Thorac Surg 1992; 53:903.</a></li><li><a class="nounderline abstract_t">VAMOS G, PAPP A. [Pancoast's syndrome and pulmonary tuberculosis]. Schweiz Z Tuberc Pneumonol 1960; 17:423.</a></li><li><a class="nounderline abstract_t">Stanley SL Jr, Lusk RH. Thoracic actinomycosis presenting as a brachial plexus syndrome. Thorax 1985; 40:74.</a></li><li><a class="nounderline abstract_t">Collins PW, de Lord C, Newland AC. Pancoast's tumour due to aspergilloma. Lancet 1990; 336:1595.</a></li><li><a class="nounderline abstract_t">Simpson FG, Morgan M, Cooke NJ. Pancoast's syndrome associated with invasive aspergillosis. Thorax 1986; 41:156.</a></li><li><a class="nounderline abstract_t">Mitchell DH, Sorrell TC. Pancoast's syndrome due to pulmonary infection with Cryptococcus neoformans variety gattii. Clin Infect Dis 1992; 14:1142.</a></li><li><a class="nounderline abstract_t">Ziomek S, Weinstein W, Margulies M, Braun RA. Primary pulmonary cryptococcosis presenting as a superior sulcus tumor. Ann Thorac Surg 1992; 53:892.</a></li><li><a class="nounderline abstract_t">Gotterer N, Lossos I, Breuer R. Pancoast's syndrome caused by primary pulmonary hydatid cyst. Respir Med 1990; 84:169.</a></li><li><a class="nounderline abstract_t">Aletras H, Papaconstantinou C. Pancoast's syndrome following an intrapleural rupture of a hepatic echinococcus cyst. Scand J Thorac Cardiovasc Surg 1982; 16:283.</a></li><li><a class="nounderline abstract_t">Rong SH. Carotid pseudoaneurysm simulating Pancoast tumor. AJR Am J Roentgenol 1984; 142:495.</a></li><li><a class="nounderline abstract_t">Gibney RT, Connolly TP. Pulmonary amyloid nodule simulating pancoast tumor. J Can Assoc Radiol 1984; 35:90.</a></li><li><a class="nounderline abstract_t">Urschel JD, Hameed SM, Grewal RP. Neurogenic thoracic outlet syndromes. Postgrad Med J 1994; 70:785.</a></li><li><a class="nounderline abstract_t">Takasugi JE, Rapoport S, Shaw C. Superior sulcus tumors: the role of imaging. J Thorac Imaging 1989; 4:41.</a></li><li><a class="nounderline abstract_t">Hamlin DJ, Burgener FA. CT, including sagittal and coronal reconstruction, in the evaluation of pancoast tumors. J Comput Tomogr 1982; 6:43.</a></li><li><a class="nounderline abstract_t">Heelan RT, Demas BE, Caravelli JF, et al. Superior sulcus tumors: CT and MR imaging. Radiology 1989; 170:637.</a></li><li><a class="nounderline abstract_t">Pennes DR, Glazer GM, Wimbish KJ, et al. Chest wall invasion by lung cancer: limitations of CT evaluation. AJR Am J Roentgenol 1985; 144:507.</a></li><li><a class="nounderline abstract_t">Webb WR, Gatsonis C, Zerhouni EA, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 1991; 178:705.</a></li><li><a class="nounderline abstract_t">Webb WR, Sostman HD. MR imaging of thoracic disease: clinical uses. Radiology 1992; 182:621.</a></li><li><a class="nounderline abstract_t">Musset D, Grenier P, Carette MF, et al. Primary lung cancer staging: prospective comparative study of MR imaging with CT. Radiology 1986; 160:607.</a></li><li><a class="nounderline abstract_t">McLoud TC, Filion RB, Edelman RR, Shepard JA. MR imaging of superior sulcus carcinoma. J Comput Assist Tomogr 1989; 13:233.</a></li><li><a class="nounderline abstract_t">Webb WR. The role of magnetic resonance imaging in the assessment of patients with lung cancer: a comparison with computed tomography. J Thorac Imaging 1989; 4:65.</a></li><li><a class="nounderline abstract_t">Rapoport S, Blair DN, McCarthy SM, et al. Brachial plexus: correlation of MR imaging with CT and pathologic findings. Radiology 1988; 167:161.</a></li><li><a class="nounderline abstract_t">Laissy JP, Soyer P, Sekkal SR, et al. Assessment of vascular involvement with magnetic resonance angiography (MRA) in Pancoast syndrome. Magn Reson Imaging 1995; 13:523.</a></li><li><a class="nounderline abstract_t">Martini N, Heelan R, Westcott J, et al. Comparative merits of conventional, computed tomographic, and magnetic resonance imaging in assessing mediastinal involvement in surgically confirmed lung carcinoma. J Thorac Cardiovasc Surg 1985; 90:639.</a></li><li><a class="nounderline abstract_t">Heelan RT, Martini N, Westcott JW, et al. Carcinomatous involvement of the hilum and mediastinum: computed tomographic and magnetic resonance evaluation. Radiology 1985; 156:111.</a></li><li><a class="nounderline abstract_t">Remmen HJ, Lacquet LK, Van Son JA, et al. Surgical treatment of Pancoast tumor. J Cardiovasc Surg (Torino) 1993; 34:157.</a></li><li><a class="nounderline abstract_t">Stanford W, Barnes RP, Tucker AR. Influence of staging in superior sulcus (Pancoast) tumors of the lung. Ann Thorac Surg 1980; 29:406.</a></li><li><a class="nounderline abstract_t">Wright CD, Moncure AC, Shepard JA, et al. Superior sulcus lung tumors. Results of combined treatment (irradiation and radical resection). J Thorac Cardiovasc Surg 1987; 94:69.</a></li><li><a class="nounderline abstract_t">Shah H, Anker CJ, Bogart J, et al. Brain: the common site of relapse in patients with pancoast or superior sulcus tumors. J Thorac Oncol 2006; 1:1020.</a></li><li><a class="nounderline abstract_t">Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 2021; 398:1344.</a></li><li><a class="nounderline abstract_t">Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 2020; 383:1711.</a></li><li><a class="nounderline abstract_t">Buderi SI, Shackcloth M, Woolley S. Does induction chemoradiotherapy increase survival in patients with Pancoast tumour? Interact Cardiovasc Thorac Surg 2016; 23:821.</a></li><li><a class="nounderline abstract_t">Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg 2001; 121:472.</a></li><li><a class="nounderline abstract_t">Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 2007; 25:313.</a></li><li><a class="nounderline abstract_t">Kunitoh H, Kato H, Tsuboi M, et al. Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. J Clin Oncol 2008; 26:644.</a></li><li><a class="nounderline abstract_t">Pourel N, Santelmo N, Naafa N, et al. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response. Eur J Cardiothorac Surg 2008; 33:829.</a></li><li><a class="nounderline abstract_t">Wright CD, Menard MT, Wain JC, et al. Induction chemoradiation compared with induction radiation for lung cancer involving the superior sulcus. Ann Thorac Surg 2002; 73:1541.</a></li><li><a class="nounderline abstract_t">Kwong KF, Edelman MJ, Suntharalingam M, et al. High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. J Thorac Cardiovasc Surg 2005; 129:1250.</a></li><li><a class="nounderline abstract_t">Kernstine KH, Moon J, Kraut MJ, et al. Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 2014; 98:402.</a></li><li><a class="nounderline abstract_t">Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26:5755.</a></li><li><a class="nounderline abstract_t">Ginsberg RJ. Resection of a superior sulcus tumor. Chest Surg Clin N Am 1995; 5:315.</a></li><li><a class="nounderline abstract_t">Kent MS, Bilsky MH, Rusch VW. Resection of superior sulcus tumors (posterior approach). Thorac Surg Clin 2004; 14:217.</a></li><li><a class="nounderline abstract_t">Dartevelle PG, Chapelier AR, Macchiarini P, et al. Anterior transcervical-thoracic approach for radical resection of lung tumors invading the thoracic inlet. J Thorac Cardiovasc Surg 1993; 105:1025.</a></li><li><a class="nounderline abstract_t">Macchiarini P. Resection of superior sulcus carcinomas (anterior approach). Thorac Surg Clin 2004; 14:229.</a></li><li><a class="nounderline abstract_t">Masaoka A, Ito Y, Yasumitsu T. Anterior approach for tumor of the superior sulcus. J Thorac Cardiovasc Surg 1979; 78:413.</a></li><li><a class="nounderline abstract_t">Korst RJ, Burt ME. Cervicothoracic tumors: results of resection by the "hemi-clamshell" approach. J Thorac Cardiovasc Surg 1998; 115:286.</a></li><li><a class="nounderline abstract_t">Rusca M, Carbognani P, Bobbio P. The modified "hemi-clamshell" approach for tumors of the cervicothoracic junction. Ann Thorac Surg 2000; 69:1961.</a></li><li><a class="nounderline abstract_t">Ginsberg RJ, Martini N, Zaman M, et al. Influence of surgical resection and brachytherapy in the management of superior sulcus tumor. Ann Thorac Surg 1994; 57:1440.</a></li><li><a class="nounderline abstract_t">Martinod E, D'Audiffret A, Thomas P, et al. Management of superior sulcus tumors: experience with 139 cases treated by surgical resection. Ann Thorac Surg 2002; 73:1534.</a></li><li><a class="nounderline abstract_t">Gandhi S, Walsh GL, Komaki R, et al. A multidisciplinary surgical approach to superior sulcus tumors with vertebral invasion. Ann Thorac Surg 1999; 68:1778.</a></li><li><a class="nounderline abstract_t">York JE, Walsh GL, Lang FF, et al. Combined chest wall resection with vertebrectomy and spinal reconstruction for the treatment of Pancoast tumors. J Neurosurg 1999; 91:74.</a></li><li><a class="nounderline abstract_t">Bilsky MH, Vitaz TW, Boland PJ, et al. Surgical treatment of superior sulcus tumors with spinal and brachial plexus involvement. J Neurosurg 2002; 97:301.</a></li><li><a class="nounderline abstract_t">Shaw RR. Pancoast's tumor. Ann Thorac Surg 1984; 37:343.</a></li><li><a class="nounderline abstract_t">Rusch VW. Management of Pancoast tumours. Lancet Oncol 2006; 7:997.</a></li><li><a class="nounderline abstract_t">Narayan S, Thomas CR Jr. Multimodality therapy for Pancoast tumor. Nat Clin Pract Oncol 2006; 3:484.</a></li><li><a class="nounderline abstract_t">Hagan MP, Choi NC, Mathisen DJ, et al. Superior sulcus lung tumors: impact of local control on survival. J Thorac Cardiovasc Surg 1999; 117:1086.</a></li><li><a class="nounderline abstract_t">Neal CR, Amdur RJ, Mendenhall WM, et al. Pancoast tumor: radiation therapy alone versus preoperative radiation therapy and surgery. Int J Radiat Oncol Biol Phys 1991; 21:651.</a></li><li><a class="nounderline abstract_t">Attar S, Krasna MJ, Sonett JR, et al. Superior sulcus (Pancoast) tumor: experience with 105 patients. Ann Thorac Surg 1998; 66:193.</a></li><li><a class="nounderline abstract_t">Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374:379.</a></li><li class="breakAll">Temeck BK, Okunieff PG, Pass HI. Chest wall disease including superior sulcus tumors. In: Lung Cancer: Principles and Practice, Pass HI, Mitchell JB, Johnson DH, Turrisi AT (Eds), Lippincott-Raven Publishers, Philadelphia 1996. p.585.</li><li><a class="nounderline abstract_t">Rusch VW, Parekh KR, Leon L, et al. Factors determining outcome after surgical resection of T3 and T4 lung cancers of the superior sulcus. J Thorac Cardiovasc Surg 2000; 119:1147.</a></li><li><a class="nounderline abstract_t">Bahce I, Vos CG, Dickhoff C, et al. Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC. Lung Cancer 2014; 85:205.</a></li><li><a class="nounderline abstract_t">Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330.</a></li><li class="breakAll">National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (Accessed on March 02, 2020).</li></ol></div><div id="topicVersionRevision">Topic 4605 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Superior pulmonary sulcus tumor</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1186286" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Carcinomas in the superior pulmonary sulcus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6860000" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Concerning the Pancoast tumor: what is the superior pulmonary sulcus?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9358132" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Superior pulmonary sulcus tumors and Pancoast's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6202389" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : External radiation in the management of superior sulcus tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3375955" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Superior pulmonary sulcus carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3800479" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pancoast tumors: improved survival with preoperative and postoperative radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/287414" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Carcinoma of the superior pulmonary sulcus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7284959" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Superior sulcus tumors: results of irradiation of 36 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Preoperative radiation therapy for superior sulcus lesions</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Preoperative radiation therapy for superior sulcus lesions</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4286514" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Thoracic inlet tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7277655" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Upper body pain: possible tipoff to Pancoast tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3772415" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Factors affecting survival in superior sulcus tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4816129" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pulmonary needle aspiration biopsy in the diagnosis of Pancoast tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2445929" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The combined neurosurgical-thoracic management of superior sulcus tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8229248" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pancoast tumor as a cause of reflex sympathetic dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2727538" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : [Paroxysmal hemicrania preceding Pancoast's syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2331828" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : [Harlequin syndrome (unilateral flushing and sweating attack) due to a spinal invasion of the left apical lung cancer].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8410029" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Sensory disorder of the chest as presenting symptom of lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4004404" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cervical approach for percutaneous needle biopsy of Pancoast tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3289832" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ultrasonography of Pancoast tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3475609" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The role of fiberoptic bronchoscopy and transbronchial biopsy in the diagnosis of Pancoast's tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3475609" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The role of fiberoptic bronchoscopy and transbronchial biopsy in the diagnosis of Pancoast's tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8179375" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Superior sulcus tumors: combined modality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3629433" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Treatment of superior sulcus tumor (Pancoast tumor).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2417689" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Carcinoma of the superior pulmonary sulcus treated with surgery and/or radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2380092" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Superior sulcus tumors: treatment selection and results for 85 patients without metastasis (Mo) at presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10813231" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pancoast tumors of the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21713767" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A prospective phase 2 study of surgery followed by chemotherapy and radiation for superior sulcus tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8279890" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Combined radiosurgical treatment of Pancoast tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6290145" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pancoast's syndrome and small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30032833" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30032833" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8383065" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pancoast syndrome: an unusual presentation of adenoid cystic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8431033" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Primary hemangiopericytoma presenting as a Pancoast tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3754528" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Bilateral Pancoast's syndrome in a patient with carcinoma of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11336324" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hepatocellular carcinoma with Pancoast's syndrome as an initial symptom: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2038737" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Thyroid carcinoma presenting as Pancoast's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6430003" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pancoast's syndrome in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6632892" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pancoast syndrome caused by extramedullary plasmacytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8153951" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pancoast syndrome caused by a high grade B cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9415361" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Non-Hodgkin's lymphoma presenting as Pancoast's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21030854" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pancoast's syndrome secondary to infectious etiologies: a not so uncommon occurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1661891" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Extrapulmonary lymphomatoid granulomatosis presenting as Pancoast's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1948800" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pancoast's syndrome due to Pseudomonas aeruginosa infection of the lung apex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1570995" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pancoast syndrome: an unusual complication of pulmonary infection by Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13779843" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : [Pancoast's syndrome and pulmonary tuberculosis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3969660" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Thoracic actinomycosis presenting as a brachial plexus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1979418" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pancoast's tumour due to aspergilloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3704984" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pancoast's syndrome associated with invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1600018" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pancoast's syndrome due to pulmonary infection with Cryptococcus neoformans variety gattii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1570991" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Primary pulmonary cryptococcosis presenting as a superior sulcus tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2371442" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pancoast's syndrome caused by primary pulmonary hydatid cyst.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7170617" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pancoast's syndrome following an intrapleural rupture of a hepatic echinococcus cyst.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6607632" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Carotid pseudoaneurysm simulating Pancoast tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6725379" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Pulmonary amyloid nodule simulating pancoast tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7824410" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Neurogenic thoracic outlet syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2643714" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Superior sulcus tumors: the role of imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7094615" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : CT, including sagittal and coronal reconstruction, in the evaluation of pancoast tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2916014" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Superior sulcus tumors: CT and MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3871560" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Chest wall invasion by lung cancer: limitations of CT evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1847239" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1311115" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : MR imaging of thoracic disease: clinical uses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2426726" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Primary lung cancer staging: prospective comparative study of MR imaging with CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2925909" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : MR imaging of superior sulcus carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2654410" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The role of magnetic resonance imaging in the assessment of patients with lung cancer: a comparison with computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3347719" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Brachial plexus: correlation of MR imaging with CT and pathologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7674847" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Assessment of vascular involvement with magnetic resonance angiography (MRA) in Pancoast syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4058036" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Comparative merits of conventional, computed tomographic, and magnetic resonance imaging in assessing mediastinal involvement in surgically confirmed lung carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4001396" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Carcinomatous involvement of the hilum and mediastinum: computed tomographic and magnetic resonance evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8320251" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Surgical treatment of Pancoast tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7377881" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Influence of staging in superior sulcus (Pancoast) tumors of the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3600010" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Superior sulcus lung tumors. Results of combined treatment (irradiation and radical resection).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17409988" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Brain: the common site of relapse in patients with pancoast or superior sulcus tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34555333" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32955177" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27365009" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Does induction chemoradiotherapy increase survival in patients with Pancoast tumour?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11241082" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17235046" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18235125" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18367406" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12022546" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Induction chemoradiation compared with induction radiation for lung cancer involving the superior sulcus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15942564" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24980603" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19001323" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7613967" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Resection of a superior sulcus tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15382298" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Resection of superior sulcus tumors (posterior approach).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8080467" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Anterior transcervical-thoracic approach for radical resection of lung tumors invading the thoracic inlet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15382299" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Resection of superior sulcus carcinomas (anterior approach).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/470421" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Anterior approach for tumor of the superior sulcus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9475522" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Cervicothoracic tumors: results of resection by the "hemi-clamshell" approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10892967" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The modified "hemi-clamshell" approach for tumors of the cervicothoracic junction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8010786" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Influence of surgical resection and brachytherapy in the management of superior sulcus tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12022545" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Management of superior sulcus tumors: experience with 139 cases treated by surgical resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585058" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : A multidisciplinary surgical approach to superior sulcus tumors with vertebral invasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10419372" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Combined chest wall resection with vertebrectomy and spinal reconstruction for the treatment of Pancoast tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12408383" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Surgical treatment of superior sulcus tumors with spinal and brachial plexus involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6712336" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Pancoast's tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17138221" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Management of Pancoast tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16955087" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Multimodality therapy for Pancoast tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10343256" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Superior sulcus lung tumors: impact of local control on survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1869459" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Pancoast tumor: radiation therapy alone versus preoperative radiation therapy and surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9692463" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Superior sulcus (Pancoast) tumor: experience with 105 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19632716" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19632716" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10838531" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Factors determining outcome after surgical resection of T3 and T4 lung cancers of the superior sulcus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24854401" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14691125" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
